Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

New England Journal of Medicine, Journal Year: 2023, Volume and Issue: 388(18), P. 1657 - 1667

Published: May 3, 2023

In a previous phase 3 trial, treatment with trifluridine-tipiracil (FTD-TPI) prolonged overall survival among patients metastatic colorectal cancer. Preliminary data from single-group and randomized 2 trials suggest that FTD-TPI in addition to bevacizumab has the potential extend survival.We randomly assigned, 1:1 ratio, adult who had received no more than two chemotherapy regimens for of advanced cancer receive plus (combination group) or alone (FTD-TPI group). The primary end point was survival. Secondary points were progression-free safety, including time worsening Eastern Cooperative Oncology Group (ECOG) performance-status score 0 1 (on scale 5, higher scores indicating greater disability).A total 246 assigned each group. median 10.8 months combination group 7.5 (hazard ratio death, 0.61; 95% confidence interval [CI], 0.49 0.77; P<0.001). 5.6 2.4 disease progression 0.44; CI, 0.36 0.54; most common adverse events both groups neutropenia, nausea, anemia. No treatment-related deaths reported. ECOG 9.3 6.3 0.43 0.67).Among refractory cancer, resulted longer alone. (Funded by Servier Taiho Oncology; SUNLIGHT ClinicalTrials.gov number, NCT04737187; EudraCT 2020-001976-14.).

Language: Английский

---

Therapeutic landscape and future direction of metastatic colorectal cancer

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2023, Volume and Issue: 20(5), P. 306 - 322

Published: Jan. 20, 2023

Language: Английский

---

Current Targeted Therapy for Metastatic Colorectal Cancer

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(2), P. 1702 - 1702

Published: Jan. 15, 2023

Colorectal cancer (CRC) is the third most common type of and second leading cause deaths worldwide. Surgery or surgery plus radiotherapy and/or chemotherapy for patients with metastatic CRC (mCRC) were accepted as main therapeutic strategies until early 2000s, when targeted drugs, like cetuximab bevacizumab, developed. The use drugs in clinical practice has significantly increased patients’ overall survival. To date, emergence several types opened new possibilities revealed prospects mCRC treatment. Therapeutic are continually being updated to select suitable based on results trials that currently underway. This review discusses up-to date molecular evidence therapy summarizes Food Drug Administration-approved including trials. We also explain their mechanisms action how these affect choice a therapy.

Language: Английский

---

Drug-tolerant persister cells in cancer: the cutting edges and future directions

Nature Reviews Clinical Oncology, Journal Year: 2023, Volume and Issue: 20(11), P. 799 - 813

Published: Sept. 25, 2023

Language: Английский

---

Colorectal cancer

The Lancet, Journal Year: 2024, Volume and Issue: 404(10449), P. 294 - 310

Published: June 20, 2024

Language: Английский

---

Systemic treatment for metastatic colorectal cancer

World Journal of Gastroenterology, Journal Year: 2023, Volume and Issue: 29(10), P. 1569 - 1588

Published: March 14, 2023

Significant progress has been achieved in the treatment of metastatic colorectal cancer (mCRC) patients during last 20 years. There are currently numerous treatments available for first-line mCRC. Sophisticated molecular technologies have developed to reveal novel prognostic and predictive biomarkers CRC. The development next-generation sequencing whole-exome sequencing, which strong new tools discovery facilitate delivery customized treatment, resulted tremendous breakthroughs DNA technology recent appropriate adjuvant mCRC determined by tumor stage, presence high-risk pathologic characteristics, microsatellite instability status, patient age, performance status. Chemotherapy, targeted therapy, immunotherapy main systemic with Despite fact that these choices increased overall survival mCRC, remains optimal individuals non-metastatic disease. being used support our ability practice personalized medicine; practical aspects applying regular clinical practice; evolution chemotherapy, strategies front-line setting all reviewed here.

Language: Английский

---

Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidance

CA A Cancer Journal for Clinicians, Journal Year: 2024, Volume and Issue: 74(3), P. 264 - 285

Published: Jan. 4, 2024

Abstract The last decade has seen rapid progress in the use of genomic tests, including gene panels, whole‐exome sequencing, and whole‐genome research clinical cancer care. These advances have created expansive opportunities to characterize molecular attributes cancer, revealing a subset cancer‐associated aberrations called driver mutations . identification these can unearth vulnerabilities cells targeted therapeutics, which led development approval novel diagnostics personalized interventions various malignancies. applications this modern approach, often referred as precision oncology or medicine , are already becoming staple care will expand exponentially over coming years. Although tests lead better outcomes by informing risk, prognosis, therapeutic selection, they remain underutilized routine A contributing factor is lack understanding their utility difficulty results interpretation broad community. Practical guidelines on how interpret integrate information setting, addressed clinicians without expertise genomics, currently limited. Building upon foundations concept oncology, authors developed practical guidance aid test that help inform decision making for patients with cancer. They also discuss challenges prevent wider implementation oncology.

Language: Английский

---

Recent developments in immunotherapy for gastrointestinal tract cancers

Journal of Hematology & Oncology, Journal Year: 2024, Volume and Issue: 17(1)

Published: Aug. 9, 2024

The past few decades have witnessed the rise of immunotherapy for Gastrointestinal (GI) tract cancers. role immune checkpoint inhibitors (ICIs), particularly programmed death protein 1 (PD-1) and PD ligand-1 antibodies, has become increasingly pivotal in treatment advanced perioperative GI Currently, anti-PD-1 plus chemotherapy is considered as first-line regimen unselected gastric/gastroesophageal junction adenocarcinoma (G/GEJC), mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer (CRC), esophageal (EC). In addition, encouraging performance claudin18.2-redirected chimeric antigen receptor T-cell (CAR-T) therapy later-line cancers brings new hope cell solid tumour treatment. Nevertheless, remains yet precise, researchers are dedicated to further maximising optimising efficacy. This review summarises important research, latest progress, future directions including EC, G/GEJC, CRC.

Language: Английский

---

Targeting the EGFR signalling pathway in metastatic colorectal cancer

˜The œLancet. Gastroenterology & hepatology, Journal Year: 2024, Volume and Issue: 9(7), P. 664 - 676

Published: April 30, 2024

Language: Английский

---

Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) Study

Journal of Clinical Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 4, 2025

PURPOSE The FIRE-4 study randomly assigned patients with first-line RAS wild-type ( wt) metastatic colorectal cancer to either flourouracil (FU), folinic acid, and irinotecan (FOLFIRI) plus cetuximab until progression or intolerable toxicity (standard arm) FOLFIRI followed by a switch maintenance treatment using FU bevacizumab (experimental arm). Here, we investigate the relevance of liquid biopsy (LB) BRAF testing compared tissue-based analyses. PATIENTS AND METHODS LBs were taken at baseline during analyzed for V600E mutations in vitro diagnostics–certified ONCOBEAM procedure (Sysmex Inostics) digital-droplet polymerase chain reaction technology. RESULTS Six hundred seventy-two wt assigned. 540 evaluable baseline. Of those, 70 (13%) mutant mut) 38 (7%) mutant. mut had significantly shorter survival (progression-free [PFS], 9.0 months v 11.5 months; P < .001; hazard ratio [HR], 1.66; overall [OS], 22.1 33.6 HR, 1.85). numerically greater benefit from early continuation FOLFIRI/cetuximab (PFS, 10.1 6.4 0.82; OS, 24.9 16.3 0.57). Patients mutation LB showed poor outcome 5.4 12.0 months). On basis serial analyses, conversion rate disease was higher arm continuous administration than arm. CONCLUSION allows detection deemed on tissue These show characteristics expected - -mutant tissue. thus confirms high clinical performed before start therapy.

Language: Английский

---